Key result
Diabetes linked to ~50% higher 30-day MACCE risk and more recurrent hospitalizations after mitral TEER.
Why the study?
DM has been linked to unfavorable outcomes after mitral TEER, but existing literature contains conflicting data.
Does diabetes mellitus increase the risk of adverse outcomes in patients undergoing mitral transcatheter edge-to-edge repair?
Meta-Analysis (n=2,130)
Does diabetes mellitus increase the risk of adverse outcomes in patients undergoing mitral transcatheter edge-to-edge repair?
Effect estimate: OR 1.50 (95% CI 1.08-2.09)
p-value: p=0.02
Diabetes mellitus is associated with an increased risk of 30-day MACCE and recurrent hospitalizations following Mitral TEER, suggesting it should be considered a predictor of adverse outcomes.
Diabetes mellitus may signal higher short-term MACCE risk after mitral TEER; leaves open whether risk modification improves outcomes in trials.
Diabetes mellitus (DM) has been linked to unfavorable outcomes in patients undergoing Mitral Transcatheter Edge-to-Edge Repair (TEER). Nevertheless, the literature contains conflicting data. This meta-analysis aimed to assess the impact of DM on outcomes following Mitral TEER. We searched PubMed, Scopus, and Medline for studies reporting outcomes following mitral TEER in diabetic and non-diabetic patients. Using a random-effects model, we determined the pooled odds ratio (OR) for clinical outcomes in patients who underwent Mitral TEER, regardless of their diabetes status. We included four studies with 2130 patients. DM was present in 31 % of the population, with a mean age of 73.9 (±8.2) years, 50.2 % of males, and 30 % of the population being obese. Patients with DM were more likely to be obese compared to patients without DM. In this meta-analysis, individuals with DM exhibited a higher 30-day MACCE (OR: 1.50, 95 % CI: 1.08–2.09, p = 0.02) and all-cause recurrent hospitalizations (OR: 1.36, 95 % CI: 1.07–1.72, p = 0.01) compared to those without diabetes. However, the difference in 30-day all-cause mortality (OR: 1.20, 95 % CI: 0.92–1.56, p = 0.19) and in-hospital all-cause mortality (OR: 0.92, 95 % CI: 0.51–1.67, p = 0.78) was not statistically significant between the two groups. DM is associated with an increased risk of 30-day MACCE and recurrent hospitalizations following Mitral TEER. Consequently, DM should be regarded as a predictor of adverse outcomes. Future, well-designed prospective randomized trials are necessary to evaluate the mid-term impact of DM on MACCE. • Diabetes Mellitus (DM) is associated with increased risks of 30-day Major adverse cardiac and cerebrovascular events and recurrent hospitalizations in patients undergoing Mitral-TEER. • The procedure duration was shorter among the individuals with diabetes than those without diabetes, and the number of implanted clips was comparable in both groups at 1.4 ± 0.6. • No significant difference in in-hospital and 30-day mortality was noted between the groups • We have not seen any significant difference in the mid-term mortality and MACCE between both the groups • Patients with diabetes mellitus had a higher prevalence of comorbidities when compared to patients without diabetes and also higher surgical risk candidates.
No takes yet. Share an insight, caveat, or question.
Chigurupati et al. (2025) conducted a meta-analysis in Mitral Transcatheter Edge-to-Edge Repair (TEER) (n=2,130). Diabetes Mellitus (DM) vs. Without diabetes was evaluated on 30-day MACCE (OR 1.50, 95% CI 1.08-2.09, p=0.02). Diabetes mellitus was associated with a higher risk of 30-day MACCE (OR 1.50; 95% CI 1.08-2.09; p=0.02) and recurrent hospitalizations following mitral TEER compared to non-diabetic patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: